Subcutaneous · GLP-1 agonist
GL0034 / utreglutide
2 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
2
Active
2
Recruiting
2
Completed
0
Sites
24
Countries
2
Endpoints
10
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
1
Phase 2
1
Trials by status
Recruiting
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Glycemic / diabetes
4
Safety / tolerability / PK
4
Weight & body composition
2
Most-measured metrics
Top 20 metrics across this asset's endpoints
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
2 of 2
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT07282743Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus | GL0034 / utreglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 2 | Recruiting | 21 | Apr 2027 | — | |
| NCT07385547Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency | GL0034 / utreglutide Healthy volunteers, Renal impairment | BMI 18-42 | Ph 1 | Recruiting | 3 | Sep 2026 | — |